Martin de la Fuente, Laura http://orcid.org/0000-0002-3618-8282
Westbom-Fremer, Sofia
Arildsen, Nicolai Skovbjerg
Hartman, Linda
Malander, Susanne
Kannisto, Päivi
Måsbäck, Anna
Hedenfalk, Ingrid
Funding for this research was provided by:
Cancerfonden (2015/486)
Gunnar Nilssons Cancerstiftelse (2017/728)
Fru Berta Kamprads Stiftelse (2017/22)
Stiftelsen Konung Gustaf V:s Jubileumsfond (2017/174161)
the Lund University Hospital Research Foundation (2017-033)
governmental funding of clinical research within the National Health Services (2014/10601)
the Cancer and Allergy Foundation (2017/174161)
Article History
Received: 11 October 2019
Revised: 7 January 2020
Accepted: 9 January 2020
First Online: 24 January 2020
Compliance with ethical standards
: Ethical approval for this study was granted by the Ethics Committee at Lund University, Sweden, waiving the requirement for informed consent.
: Dr. Malander has received honoraria from AstraZeneca and Tesaro for advisory board participation during the conduct of this study. Dr. Martin de la Fuente received grant support from Roche in collaboration with the Swedish Society of Gynecological Oncology. The rest of the authors declare that they have no conflicts of interest to report.